Answers are grounded in this paper and cite their sources.
Neurodevelopmental disorders globally affect approximately 15% of children and adolescents, but many disorders do not have mouse models, thus limiting our ability to further understand them and ultimately develop treatments. In our study, we developed a novel mouse line to model 3p25.3 microdeletion syndrome ( 6qE3 del/+ ) that reliably recapitulates key features of the syndrome. 6qE3 del/+ mice display congenital heart defects, craniofacial defects, skeletal anomalies and subtle brain changes. We also generated another neurodevelopmental disorder model for a gene often included in the deleted region, Brpf1 , and found that congenital heart defects and craniofacial defects may be partly attributable to the heterozygous loss of Brpf1 in 6qE3 del/+ mice. Together our work offers new neurodevelopment models, and provides evidence that treatments developed for Brpf1 haploinsufficiency may also benefit 3p25.3 microdeletion syndrome.
No takes yet. Share an insight, caveat, or question.
Morgan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: